Alterations in Mitochondrial Function in Pulmonary Vascular Diseases
Authors:
Open Access
- 7 March 2025
- journal article
- research article
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 42 (7-9) , 361-377
Abstract
Aims: Alterations of mitochondrial bioenergetics and arginine metabolism are universally present and mechanistically linked to pulmonary arterial hypertension (PAH), but there is little knowledge of arginine metabolism and mitochondrial functions across the different pulmonary hypertension (PH) groups. We hypothesize that abnormalities in mitochondrial functions are present across all PH groups and associated with clinical phenotypes. We test the hypothesis in PH patients and healthy controls from the Pulmonary Vascular Disease Phenomics Program cohort, who had comprehensive clinical phenotyping and follow-up for at least 4 years for death or transplant status. Mitochondrial transmembrane potential, superoxide production, and mass were measured by flow cytometry in fresh platelets. Metabolomics analysis was performed on plasma samples. Global arginine bioavailability was calculated as the ratio of arginine/(ornithine+citrulline). Results: Global arginine bioavailability is consistently lower than controls in all PH groups. Although the mitochondrial mass is similar across all PH groups and controls, superoxide production and transmembrane potential vary across groups. Mitochondrial superoxide is higher in group 1 PAH and lowest in group 3 compared with other groups, while transmembrane potential is lower in group 1 PAH than controls or group 3. The alterations in mitochondrial functions of group 1 PAH are associated with changes in fatty acid metabolism. Mitochondrial transmembrane potential in group 1 PAH is associated with transplant-free survival. Conclusion: While alterations in mitochondrial function are found in all PH groups, group 1 PAH has a unique mitochondrial phenotype with greater superoxide and lower transmembrane potential linked to fatty acid metabolism, and clinically to survival. Antioxid. Redox Signal. 42, 361–377.Keywords
This publication has 72 references indexed in Scilit:
- Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial HypertensionChest, 2021
- Modeling continuous response variables using ordinal regressionStatistics in Medicine, 2017
- Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertensionJournal of Molecular Medicine, 2014
- The Metabolic Basis of Pulmonary Arterial HypertensionCell Metabolism, 2014
- Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertensionJournal of Molecular Medicine, 2013
- Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycleJournal of Molecular Medicine, 2011
- The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricleJournal of Molecular Medicine, 2009
- Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell DiseaseJAMA, 2005
- High Levels of Nitric Oxide in Individuals with Pulmonary Hypertension Receiving Epoprostenol TherapyLung, 2001
- Abnormalities of the electron transport chain in idiopathic parkinson's diseaseAnnals of Neurology, 1989